Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Debt (2019 - 2024)

Historic Total Debt for Seres Therapeutics (MCRB) over the last 7 years, with Q2 2024 value amounting to $102.5 million.

  • Seres Therapeutics' Total Debt rose 173.91% to $102.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $102.5 million, marking a year-over-year increase of 173.91%. This contributed to the annual value of $101.5 million for FY2023, which is 10071.55% up from last year.
  • As of Q2 2024, Seres Therapeutics' Total Debt stood at $102.5 million, which was up 173.91% from $102.0 million recorded in Q1 2024.
  • Seres Therapeutics' 5-year Total Debt high stood at $102.5 million for Q2 2024, and its period low was $16.1 million during Q3 2021.
  • Moreover, its 5-year median value for Total Debt was $50.5 million (2022), whereas its average is $52.4 million.
  • As far as peak fluctuations go, Seres Therapeutics' Total Debt plummeted by 3547.26% in 2021, and later surged by 21554.88% in 2022.
  • Over the past 5 years, Seres Therapeutics' Total Debt (Quarter) stood at $24.6 million in 2020, then increased by 0.02% to $24.6 million in 2021, then surged by 105.3% to $50.6 million in 2022, then skyrocketed by 100.72% to $101.5 million in 2023, then increased by 0.94% to $102.5 million in 2024.
  • Its Total Debt was $102.5 million in Q2 2024, compared to $102.0 million in Q1 2024 and $101.5 million in Q4 2023.